Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Magnetic Resonance Imaging Sub-study
Status:
Terminated
Trial end date:
2021-03-21
Target enrollment:
Participant gender:
Summary
TRIDENT Main Study:
TRIDENT is a multicentre, international, double-blinded, placebo-controlled, parallel-group,
randomised controlled trial of a fixed low-dose combination BP-lowering pill ("Triple Pill")
strategy on top of standard of care, in patients with a history of acute intracerebral
haemorrhage (ICH) and systolic blood pressure (SBP) levels defined as 'high normal to
borderline high', and on either minimal or no BP-lowering treatment according to current
guidelines.
MRI Sub-Study Centres capable of specific MRI of the brain sequences will be identified. The
patients in the TRIDENT main study who are identified to be eligible for the MRI Sub-Study
will undergo MRI scans at baseline (6 weeks to 6 months post-randomisation) and at 36-month
follow-up time points. All data collected will be analysed centrally at the Brain and Mind
Centre (BMC) in Sydney, Australia.